Publicaciones en las que colabora con AINHOA SAGARDUY CRESPO (3)

2016

  1. Buspirone requires the intact nigrostriatal pathway to reduce the activity of the subthalamic nucleus via 5-HT1A receptors

    Experimental Neurology, Vol. 277, pp. 35-45

2014

  1. Buspirone anti-dyskinetic effect is correlated with temporal normalization of dysregulated striatal DRD1 signalling in l-DOPA-treated rats

    Neuropharmacology, Vol. 79, pp. 726-737

2012

  1. The role of the subthalamic nucleus in L-DOPA induced dyskinesia in 6-hydroxydopamine lesioned rats

    PLoS ONE, Vol. 7, Núm. 8